

DAFTAR PUSTAKA

- Andersson, K.L., Chung, R.T., 2009. Monitoring during and after antiviral therapy for hepatitis B. *Hepatology*. 49(5 Suppl): S166–S173
- Buti, M., Tsai, N., Petersen, J., Flisiak, R., Gurel, S., Krastev, Z., Schall, R.A., Flaherty, J.F., Martins, E.B., Charuworn, P., Kitrinou, K.M., Subramanian, G.M., Gane, E., Marcellin, P., 2015. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. *Dig Dis Sci*. 60:1457–1464
- Chao, D.C., Hu, K., 2013. Update on rescue therapies in patients with lamivudine-resistant chronic hepatitis B. *Dove Press Journal: Drug Des Dev Ther*. 7:777-788.
- Centers for Disease Control (CDC), 2009. Viral Hepatitis Surveillance, United States 2009. National Center for HIV/AIDS, Viral Hepatitis, STD & TB Prevention (online). <http://www.cdc.gov/hepatitis>. Akses 4 Agustus 2014.
- Centers for Disease Control (CDC), 2014. Hepatitis B at Risk (online). <http://www.cdc.gov/hepatitis/HBV/PDFs/HepBAtRisk-BW.pdf>. Akses 30 September 2014.
- Chen, J., Yang, H., Iloeje, U.H., 2009. Hepatitis B Virus DNA levels and outcomes in chronic hepatitis B. *Hepatology*. 49(5):S72-S84.
- Departemen Kesehatan Republik Indonesia (Depkes RI), 2012. Pedoman Pengendalian Hepatitis Virus (online). http://pppl.depkes.go.id/_asset/download/Pedoman%20Hepatitis%20OK.pdf. Akses 26 Agustus 2014.
- Da Silva, L.Z., Da Fonseca, L.E.P., Carrilho, F.J., Alves, J.A.F., Sitnik, R., Pinho, J.R.R., 2000. Predictive factors for response to lamivudine in chronic hepatitis B. *Rev. Inst Med trop S Paulo*. 42 (4): 189-196.
- Duarte-Rojo, A., Heathcote, E.J., 2010. Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B. *Ther Adv Gastroenterol*. 3(2):107-119.
- European Association for the Study of the Liver (EASL), 2012. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. *J Hepatol*. 57:167–185
- Gigi, E., Sykia, A., Sinakos, E., Koumerkeridis, G., Raptopoulou-Gigi, M., Bellou, A.L., Mougou, D., Orfanou, E., Vrettou, E., 2012. Virologic response and resistance to lamivudine in patients with chronic hepatitis B: a ten-year retrospective analysis. *Hippokratia*. 16, 4: 342-346.

- He, D., Guo, S., Zhu, P., Tao, S., Li, M., Huang, H., Wang, J., Wang, Y., Ding, M., 2014. Long-term outcomes after nucleos(t)ide analogue discontinuation in HBeAg-positive chronic hepatitis B patients. *Clin Microbiol Infect.* 20: O687–O693.
- Hong, S.J., Kim, Y.H., Choe, B.H., Park, H.J., Tak, W.Y., Kweon, Y.O., 2013. Current role of lamivudine regarding therapeutic response and resistance in children with chronic hepatitis B. *J Pediatr Gastroenterol Nutr.* 16(2):80-88.
- Kawanaka, M., Nishino, K., Nakamura, J., Oka, T., Urata, N., Goto, D., Suehiro, M., Kawamoto, H., Kudo, M., Yamada, G., 2014. Quantitative levels of hepatitis B virus DNA and surface antigen and the risk of hepatocellular carcinoma in patients with hepatitis B receiving long-term nucleos(t)ide analogue therapy. *Liver Cancer.* 3:41–52
- Kidd-Ljunggren, K., Miyakawa, Y., Kidd, A.H., 2002. Genetic variability in hepatitis B viruses. *J Gen Virol.* 83:1267–1280.
- Kim, J.H., Choi, Y.J., Moon, H.W., Ko, S.Y., Choe, W.H., Kwon, S.Y., 2013. HBsAg level and clinical course in patients with chronic hepatitis B treated with nucleoside analogue: five years of follow-up data. *Clin Mol Hepatol.* 19:409-416
- Kim, K-H., Kim, N.D., Seong, B-L., 2010. Discovery and Development of Anti-HBV Agents and Their Resistance. *Molecules.*15:5878-5908.
- Lai, C-L., Gane, E., Liaw, Y-F., Hsu, C-W., Thongsawat, S., Wang, Y., Chen, Y., Heathcote, C., Rasenack, J., Bzowej, N., Naoumov, N.V., Di Bisceglie, A.M., Zeuzem, S., Moon, Y.M., Goodman, Z., Chao, G., Constance, B.F., Brown, N.A., 2007. Telbivudine versus lamivudine in patients with chronic hepatitis B. *N Engl J Med.* 357:2576-2588.
- Liaw, Y., Chu, C., 2009. Hepatitis B virus infection. *The Lancet.* 373: 582-592.
- Luo, J., Li, X., Wu, Y., Lin, G., Pang, Y., Zhang X., Ao, Y., Du, Z., Zhao, X., Chong, Y., 2013. Efficacy of Entecavir treatment for up to 5 year in nucleos(t)ide naïve chronic hepatitis B patients in real life. *Int J Med Sci.* 10(4):427-433
- Mc Mahon, B.J., 2009. Natural history of chronic hepatitis B. *Am Assoc Study Liver Dis.* doi:10.1002/hep.22898.
- Mc Mahon, B.J., 2010. Natural History of Chronic Hepatitis B. In: Gitlin, N.M., Tsai, M.C.S. (ed): *Chronic Hepatitis B: an update.* Vol. 14:3.
- Osborn, M.K., 2009. Safety and efficacy of telbivudine for the treatment of chronic hepatitis B. *Ther Clin Risk Manage.* 5:789–798.

- Osborn, M.K., 2011. Safety and efficacy of entecavir for the treatment of chronic hepatitis B. *Dove Press Journal: Infect Drug Resist.* 4:55–64
- Palumbo, E., 2008. Lamivudine for chronic hepatitis B: A brief review. *Brazilian J Infect Dis.* 12(5):355-357.
- Perhimpunan Peneliti Hati Indonesia (PPHI), 2012. Konsensus Nasional Penatalaksanaan Hepatitis B di Indonesia (online). <https://www.scribd.com/doc/128643707/Konsensus-1>. Akses 30 September 2014.
- Pourkarim, M.R., Amini-Bavil-Olyaei, S., Kurbanov, F., Ranst, M.V., Tacke, F., 2014. Molecular identification of hepatitis B virus genotypes/ subgenotypes: revised classification hurdles and updated resolutions. *World J Gastroenterol.* 20(23): 7152-7168
- Previsiani, N., Lavanchy, D., Zuckerman, A.J., 2004. Hepatitis B. In: Mushawar, I.K. (ed.): *Viral Hepat Mol Biol Diagn Epidemiol Control*, pp: 32. North Chicago: WHO.
- Rx List. 2013. Tyzeka: Drug Information (online). <http://www.rxlist.com/tyzeka-drug/clinical-pharmacology.htm>. Akses 26 Agustus 2014.
- Safrin, S., 2007. Antiviral Agents. In: Katzung, B.G. (ed): *Basic & Clinical Pharmacology 10th edition*. New York: McGraw-Hill Medical.
- Santos, A.O., Alvarado-Mora, M.V., Botelho, L., Vieira, D.S., Pinho, J.R.R., Carrilho, F.J., Honda, E.R., Salcedo, J.M., 2010. Characterization of Hepatitis B virus (HBV) genotypes in patients from Rondônia, Brazil. *Virology J.* 7:315
- Schaefer, S., 2005. Hepatitis B virus: significance of genotypes. *J Viral Hepat.* 12: 111-124.
- Schweitzer, A., Horn, J., Mikolajczyk, R.T., Krause, G., Ott, J.J., 2015. Estimations of Worldwide Prevalence of Chronic Hepatitis B Virus Infection: a Systematic Review of Data Published between 1965 and 2013. *Lancet.* 386: 1546–55
- Shepard, C.W., Simard, E.P., Finelli, L., Fiore, A.E., Bell, B.P., 2006. Hepatitis B virus infection: epidemiology and vaccination. *Epidemiol Rev.* 28:112–125
- Shouval, D., 2014. The pros and cons of lamivudine vs. Entecavir in decompensated or severe acute exacerbation of chronic hepatitis B. *J Hepatol.* 60:1108–1109.
- Sulaiman, A., Lesmana, L.A., Nafrialdi, Helyanna, 2014. An observational study to evaluate the safety and efficacy of telbivudine in adults with chronic hepatitis B. *Acta Med Indiciana.* 46(1): 38-43.

- Turyadi, Thedja, M.D., Ie, S.I., Harahap, A.R., El-Khobar, K.E., Roni, M., Muljono, D.H., 2013. HBsAg, HBeAg and DNA VHB level changes and precore/basal core promoter mutations in the natural history of chronic hepatitis B in Indonesian patients. *Hepatol Int.* 7:969–980
- Van Bömmel, F., De Man, R.A., Wedemeyer, H., Deterding, K., Petersen, J., Buggisch, P., Erhardt, A., Huppe, D., Stein, K., Trojan, J., Sarrazin, C., Bocher, B.O., Spengler, U., Wasmuth, H.E., Reinders, J.G.P., Moller, B., Rhode, P., Feucht, H., Wiedenmann, B., Berg, T., 2010. Long-term efficacy of tenofovir monotherapy for hepatitis B virus monoinfected patients after failure of nucleoside/nucleotide analogues. *Hepatology.* 51:73-80
- Widita, H., Gunawan, S., Laksono, B.T., Achwan, W.A., Wilusanta, G.P., Mahendra, K., Taufiq, H.S., Soemohardjo, S., 2009. Status HBeAg dan anti HBe pada penderita infeksi hepatitis B kronik di Mataram (online). <https://biomedikamataram.wordpress.com/2009/06/07/status-hbeag-dan-anti-HBe-pada-penderita-infeksi-hepatitis-b-kronik-di-mataram/>. Akses 16 Februari 2016.
- World Health Organization (WHO), 2009. Weekly Epidemiological Record. *WHO.* 40 (84):405–420.
- Yu, H., Yuan, Q., Ge, S-X., Wang, H-Y., Zhang, Y.L., Chen, Q-R., Zhang, J., Chen, P-J., Xia, N-S., 2010. Molecular and phylogenetic analyses suggest an additional hepatitis B virus genotype ‘I’. *Journal PLoS ONE.* 5(2).e9297.
- Yu, S., Zhou, Q., Zhao, X.M., Yuan, M., Wang, C.T., Cheng, X.G., Zhang, Z.H., Liu, X.L., 2014. Comparison of the antiviral effects of different nucleos(t)ide analogues in Chinese patients with chronic hepatitis B: a head-to-head study. *Saudi J Gastroenterol.* 20(6): 350–355.
- Zeuzem, S., Gane, E., Liaw, Y., Lim, S.G., DiBisceglie, A., Buti, M., Chutaputti, A., Rasenack, J., Hou, J., O’Brien, C., Nguyen, T.T., Jia, J., Poynard, T., Belanger, B., Bao, W., Naoumov, N.V., 2009. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. *J Hepatol.* 51:11–20
- Zhao, S., Liu, E., Cheng, D., Li, Y., Wang, Y., Chen, Y., Sun, W., Yan, S., Dang, S., 2012. Comparison of entecavir and adefovir for the treatment of chronic hepatitis B. *Braz J Infect Dis.* 16(4):366–372.